| Value | ₹106.3 Cr |
|---|---|
| Execution period | 2 years |
BSE filing, NSE: BROOKS. Summary written from the filing by ALFA Finder's alert engine.
Brooks Laboratories Ltd: key numbers
- Share price
- ₹60.56
- Market cap
- ₹178.4 Cr
- Revenue (annual)
- ₹85.74 Cr
- Net profit (annual)
- ₹24.58 Cr
- P/E (TTM)
- 13.5×Sector 45.9×
- Promoter holding
- 52.62%+0.00% QoQ
- FII holding
- 0.04%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Brooks Laboratories Ltd
All →Brooks Laboratories Other Announcement
Brooks Laboratories Ltd has submitted its quarterly shareholding pattern as of September 30, 2026, in compliance with SEBI regulatory requirements.
Brooks Laboratories Merger & Restructuring
Brooks Laboratories approved a demerger of its Manufacturing Business into its wholly-owned subsidiary, Abridge Speciality Limited, through a scheme of arrangement.
Brooks Laboratories Price Movement Clarification
Brooks Laboratories informed BSE it has no additional material information to disclose regarding the recent price movement. The company attributed the share price and volume changes to purely market-driven factors.
Brooks Laboratories Management Change
Brooks Laboratories Ltd announced the resignation of Ms. Krutika Rane, Company Secretary and Compliance Officer, effective October 9, 2026.
Brooks Laboratories Annual General Meeting
Brooks Laboratories Limited conducted its 24th Annual General Meeting on September 3, 2026. Shareholders transacted ordinary business, including the adoption of financial statements and director appointments.
Brooks Laboratories Annual General Meeting
Brooks Laboratories issued an addendum to its 24th Annual General Meeting notice. The amendment modifies Resolution No. 4 regarding corporate guarantee arrangements.
Other merger & restructuring announcements
All →Symphony Merger & Restructuring Worth ₹27 Cr
Symphony will sell its Bodakdev vacant land for ₹27 Crore, versus ₹5.68 Crore book value. Sale deed is expected November 6, 2026; operations are unaffected.
- Value
- ₹27.00 Cr
Juniper Green Energy Merger & Restructuring Worth ₹0.15 Cr
Juniper Green Energy incorporated wholly owned subsidiary Juniper Green Beta Fifteen Private Limited on October 30, 2026. The company subscribed to 1,50,000 shares for Rs.0.15 Crore.
- Value
- ₹0.15 Cr
Oricon Enterprises Merger & Restructuring Worth ₹145 Cr
Oricon Enterprises sold its leasehold land and building to Anand Rathi Towers for Rs.145 Crore. The sale is completed and the buyer is unrelated to promoters.
- Value
- ₹145.0 Cr
Clean Max Enviro Energy Solutions Merger & Restructuring Worth ₹0 Cr
Sale of 26% stake in subsidiary Clean Max Alps to Bayer Vapi for ₹0.0026 Crore. The subsidiary contributed no revenue or net worth last financial year.
- Value
- ₹0.00 Cr
Vimta Labs Merger & Restructuring Worth ₹0.08 Cr
Vimta Labs incorporated wholly owned US subsidiary Vimta Labs LLC, investing about INR 0.08 Crore (USD 8,500). The contract research unit supports the parent's testing business.
- Value
- ₹0.08 Cr
Weagro Merger & Restructuring Worth ₹0.01 Cr
Weagro will incorporate a wholly-owned Singapore subsidiary, Weagro Pte Ltd, with initial investment up to SGD 100,000. The move expands its agro business into Singapore.
- Value
- ₹0.01 Cr
- Execution
- Within two months from the date of the Board decision, subject to statutory approvals.